|
KMID : 1038020210290040226
|
|
Translational and Clinical Pharmacology
2021 Volume.29 No. 4 p.226 ~ p.238
|
|
|
Determination of candesartan or olmesartan in hypertensive patient plasma using UPLC-MS/MS
|
|
Jeong Hyeon-Cheol
Seo Yo-Han
Gu Nam-Yi
Rhee Moo-Yong
Shin Kwang-Hee
|
|
|
Abstract
|
|
|
|
Candesartan and olmesartan are angiotensin II receptor blockers (ARBs) used for the treatment of hypertension and heart failure. Quantitation methods for candesartan and olmesartan were developed using ultra-high performance liquid chromatography-tandem mass spectrometry following protein precipitation. Candesartan was separated using 5 mM ammonium formate (A) and 100% acetonitrile (B) and olmesartan was separated using 2 mM ammonium formate with 0.1% formic acid (A) and 100% acetonitrile (B). Separation was performed using an isocratic method with a Thermo hypersil GOLD C18 column. Electrospray ionization was used for analyte ionization and detection of candesartan, olmesartan, and the internal standards by multiple reaction monitoring. Developed method showed excellent linearity (r > 0.99) in the concentration range of 2?500 ng/mL for candesartan and 5?2,500 ng/mL for olmesartan. Accuracies were 86.70?108.8% for candesartan and 87.87?112.6% for olmesartan. These methods were able to successfully measure plasma candesartan or olmesartan concentrations in hypertensive patients. This study can be used for pharmacokinetic studies of candesartan or olmesartan in humans.
|
|
|
KEYWORD
|
|
|
Candesartan, Olmesartan, Angiotensin II Receptor Blockers, Liquid Chromatography, Mass Spectrometry
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|